Boehringer Ingelheim receives rights to oral small molecules from Sitryx with potential purposes in a number of autoimmune issues. Relying on the progress of Boehringer’s analysis, Sitryx may obtain greater than $500 million.
The put up Boehringer Boosts Pipeline, Including Oral Small Molecules With Broad Immunology & Irritation Potential appeared first on MedCity Information.
